FindTrial
Sign In

Bronchial occlusion therapy combined with bronchial artery embolization for hemoptysis

Correlation study of bronchoscopic treatment combined with bronchial artery embolization for hemoptysis: an analysis based on medical records

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2300072242
Enrollment
Unknown
Registered
2023-06-07
Start date
2023-05-25
Completion date
Unknown
Last updated
2023-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemoptysis

Interventions

Combined therapy with bronchial artery embolization and endobronchial tamponade group:None
bronchial artery embolization group:None

Sponsors

The Second Affiliated Hospital of Fujian Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 90 Years

Inclusion criteria

Inclusion criteria: In line with the diagnostic criteria of hemoptysis; age more than 18 years old; underwent BAE or combined therapy with bronchial artery embolization and endobronchial tamponade; available follow-up data

Exclusion criteria

Exclusion criteria: 1.Severe heart disease (acute myocardial infarction, chronic heart failure, valvular heart disease, and heart failure within 6 months); 2.Contraindication to BAE; 3.Severe renal disease (acute and chronic renal insufficiency, nephrotic syndrome, nephritis, etc.) 4.Serious lung disease (pulmonary bullae, pneumothorax, mediastinal emphysema, COPD, pulmonary fibrosis, tumor, etc.)

Design outcomes

Primary

MeasureTime frame
PaO2/FiO2;—

Secondary

MeasureTime frame
PaO2;D-dimer;fibrinogen;—

Countries

China

Contacts

Public ContactLiu Dexin

The Second Affiliated Hospital of Fujian Medical University

986668471@qq.com+86 137 0696 0031

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026